Equibles does not estimate personal net worth.
Get an email with a short summary when Allogene Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALLO alertsDavid Chang is recorded as CEO at Allogene Therapeutics, Inc. (ALLO). Earlier roles on record: Board Member at Battalion Oil Corp (BATL) until March 31, 2026. Battalion Oil Corp reported in an 8-K filed April 3, 2026 that David Chang resigned as Board of Directors, effective March 31, 2026. The proxy statement of Allogene Therapeutics, Inc. reports total compensation of $4,482,208 for David Chang in fiscal 2024, including a base salary of $724,000. Disclosed compensation is on record for 7 fiscal years. David Chang has spoken on 22 earnings calls across 1 company, most recently for Allogene Therapeutics, Inc. on May 13, 2026. Allogene Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Allogene Therapeutics, Inc. includes Zachary Roberts, M.D., Ph.D. (CEO and Board Member), Geoffrey Parker (CFO), Tim Moore (CTO) and 5 others.
“On March 30, 2026, David Chang notified the Board of Directors (the "Board") of Battalion Oil Corporation (the "Company") of his decision to resign from the Board, including from his position as Chairman of the Compensation Committee and as a member of the Reserves Committee, effective March 31, 2026.”
“As we move through 2026, next-generation cell therapy is shifting from promise to proof. The field is increasingly being defined by differentiated clinical evidence rather than platform ambition alone.”
“As we close 2025 and enter what we expect to be a defining year for Allogene Therapeutics, Inc., the environment around us is shifting. Cell therapy has entered a phase defined by evidence, where progress will be measured not by speculation and promises, but by data and disciplined execution.”
“This quarter has been about conviction, conviction in our science in the path we have chosen and in the future we are building for patients. We are aware of the shifting conversation in the field.”
“This past quarter marked a period of significant advancement across our portfolio with progress that highlights how scientific excellence, rigorous decision-making, and thoughtful planning can call us into transformative momentum.”
“Today we come together at a defining moment for Allogene. A moment that potentially validates the bold forward-looking strategy we launched in January 2024. At the time, we committed to doing what no CAR T had done before.”
2019-01-01–2026-03-31
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $724,000 | $4,482,208 |
| 2023 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $724,000 | $14,063,848 |
| 2022 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $724,000 | $14,797,837 |
| 2021 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $695,000 | $10,161,454 |
| 2020 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $675,000 | $7,815,041 |
| 2019 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $600,000 | $11,192,110 |
| 2018 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $362,413 | $12,848,537 |
